Brain Stimulation for the Treatment of Tourette Syndrome
NCT ID: NCT01329198
Last Updated: 2018-06-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2009-09-30
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The trial will also examine the brain activity associated with TS and tics and explore the possibility of responsive brain stimulation (RBS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tourette Syndrome Deep Brain Stimulation
NCT02056873
Subthalamic Stimulation in Tourette's Syndrome
NCT02619084
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
NCT02253498
Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00311909
Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression
NCT05371041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The wires which house the electrodes will be implanted on both sides of the brain oriented towards the centromedian thalamus-parafascicular complex. This region of the brain has to date the greats number of documented cases revealing significant improvements in motor tics.
This region of the brain will also provide a target where physiological changes related to motor tics are likely to be discovered.
The device we propose for this study has several features that make it more suitable for use in the TS population than other devices. It is self-contained in the skull and brain, and contains no tunneled neck connector wire and no chest pacemaker deice. This will help to lessen infection, and will assist in limiting device-related fractures due to tics involving neck region. Also, the system can record electro-encephalograph data from the area of the electrodes, which will assist us in gathering information about what specific physiological changes are correlated with tics.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Delayed Activation - Deep Brain Stimulation (DBS)
Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.
* There will be a one month post-operative period during which stimulation is not turned on.
* One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
* By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
* Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days.
NeuroPace RNS® System Deep Brain Stimulator
Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
Immediate Activation - Deep Brain Stimulation (DBS)
Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency \& severity, while limiting potential stimulation-induced side-effects.
* There will be a one month post-operative period during which stimulation is not turned on.
* One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
* By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
* Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days.
NeuroPace RNS® System Deep Brain Stimulator
Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NeuroPace RNS® System Deep Brain Stimulator
Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* must have a minimum score on the primary tic rating scale
* symptoms must be causing significant impairment in functioning, making it impossible or almost impossible to do daily activities, including work or school and interactions with friends and family, causing severe distress and a poor quality of life
* symptoms have not responded well enough to medications prescribed by a neurologist or psychiatrist experienced in treating TS. Must have had trials of drugs from three different classes of drugs that have not worked.
* must have received stable and effective treatment of any other existing medical or psychological problems for the past 6 months.
* current TS related-medication(s) must be stable for at least a month without a dose change prior to surgery and must be willing to keep these medications stable and unchanged throughout the study or must be off of TS-related medications for at least three months prior to surgery
* If tics involve only one group of muscles or might be controllable by botulinum toxin treatment, must try botulinum treatment before considering surgery.
* must have a negative urine drug screen
* must give informed consent
Exclusion Criteria
* have had any previous brain surgery including deep brain stimulation, ablative capsulotomy or cingulotomy
* have another psychiatric condition (including body dysmorphic disorder, a delusional disorder or a biological brain disorder), dementia or cognitive dysfunction that would place subject at risk for worsening cognition and/or may impact ability to comply with study procedures. Also included is any other psychiatric disorder that requires medications or treatments that would interfere with the functioning of the DBS device.
* have any significant substance abuse or dependence (e.g., stimulants, alcohol, opiates, benzodiazepines) within the past six months
* have a severe medical disease including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impacts tolerability of the surgery as judged by the screening physicians
* pre-surgery MRI is considered abnormal. You may also be excluded if your brain is considered very small.
* have a history of serious suicidal behavior, are unable to control suicide attempts, or are currently at risk of suicide, in the judgement of the investigator
* have head-banging tics or tics that have the potential to damage the RNS System
* are currently pregnant or breast-feeding, plan to become pregnant during the study, or are not using effective contraception
* are currently enrolled in another investigational study
* have an implant such as a pacemaker or neurostimulator containing electrical circuitry or that generates electrical signals
* have any metal orthopedic pins or plates, metal orthodontics, or non-removable body jewelry
* require diathermy treatments during physical or occupational therapy
* have a problem that will require repeat Magnetic Resonance Imaging (MRI) scans
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Okun, MD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida Movement Disorders Center
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Okun MS, Foote KD, Wu SS, Ward HE, Bowers D, Rodriguez RL, Malaty IA, Goodman WK, Gilbert DM, Walker HC, Mink JW, Merritt S, Morishita T, Sanchez JC. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013 Jan;70(1):85-94. doi: 10.1001/jamaneurol.2013.580.
Related Links
Access external resources that provide additional context or updates about the study.
Increased Thalamic Gamma Band Activity Correlates with Symptom Relief following Deep Brain Stimulation in Humans with Tourette's Syndrome
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
414-2008- A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.